This website is intended only for United States healthcare professionals; if you are not a United States healthcare professional, please visit www.BioMarin.com
This website was developed and funded by BioMarin and is intended for healthcare professionals only. It offers a non-exhaustive selection of materials, including but not limited to publications, presentations, posters and educational materials, to support scientific exchange.
Clinical study results reflect knowledge at the study’s completion and may not be current. Review the methodology, limitations, and authors’ financial disclosures for details.
The information on this website is not medical advice and should not replace independent medical judgment or further research. Content on investigational therapeutics or uses of approved products does not confirm safety or efficacy. BioMarin does not endorse off-label use of its medicines.
As product information may vary by country, please refer to your local health authority regulations and respective approved product information for indications and safety details.

Congress Posters & Presentations

Access hypochondroplasia related posters and presentations from recent congresses.

Hypochondroplasia

Filter
Filter by:
Filter by congress:
Filter by year:

All displayed posters and presentations are protected by copyright and are intended for individual use only.

Please Note: Poster content may be unavailable or delayed. This could be due to copyright or embargo guidelines.

You may check back later or contact medinfo@bmrn.com or complete a request form to inquire about this specific material

Congress Posters and Presentations

Presentation

New

  • Congresses
  • Hypochondroplasia
  • ENDO
  • 2026

Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results From A Phase II Extension Trial

Presentation

New

  • Congresses
  • Hypochondroplasia
  • SHOX Deficiency
  • ENDO
  • 2026

Vosoritide Improves Growth in RASopathies, Aggrecan and NPR2 Deficiency: A Phase 2 Trial

Poster

New

  • Congresses
  • Hypochondroplasia
  • PES
  • 2026

Design of a randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and efficacy of vosoritide in infants and children with hypochondroplasia aged <3 years

Poster

New

  • Congresses
  • Hypochondroplasia
  • PES
  • 2026

Vosoritide Treatment Improves Linear Growth and Absolute Bone Content and Density in Children With Hypochondroplasia: A 12-Month Prospective Study

Poster

  • Congresses
  • Hypochondroplasia
  • ACMG
  • 2026

Body composition changes during 12-month vosoritide treatment in children with hypochondroplasia: a DXA-based prospective study

Poster

  • Congresses
  • Hypochondroplasia
  • ACMG
  • 2026

Complete functional map of FGFR3 variants reveals a broad spectrum of effects and underdiagnosed skeletal dysplasia

Poster

  • Congresses
  • Achondroplasia
  • Hypochondroplasia
  • ESPE-OSCAR
  • 2025
  • Impact of Disease

Achondroplasia and Hypochondroplasia in France: a nationwide epidemiological analysis

Poster

  • Congresses
  • Hypochondroplasia
  • PES
  • 2025
  • Safety Profile and Efficacy

IGF-1 Values in Hypochondroplasia and Effects of Vosoritide

Poster

  • Congresses
  • Hypochondroplasia
  • ESPE
  • 2024

Design and objectives of Study 111-902: a multicenter, prospective, and retrospective observational study of children with hypochondroplasia

Presentation

  • Congresses
  • Hypochondroplasia
  • ESPE
  • 2024
  • Clinical Trial Data

FC5: Growth and Syndromes Phase 2 Trial of Vosoritide Use in Patients with Hypochondroplasia: Pharmacokinetic/ Pharmacodynamic Analysis from 12 Month Data

Presentation

  • Congresses
  • Hypochondroplasia
  • ISDS
  • 2024

Vosoritide Improves Growth in RASopathies, ACAN and NPR2 Deficiency: Preliminary Data from a Phase 2 Trial

Presentation

  • Congresses
  • Hypochondroplasia
  • ISDS
  • 2024
  • Clinical Trial Data

Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results

Poster

  • Congresses
  • Hypochondroplasia
  • ICCBH
  • 2024
  • Burden of Disease

Comorbidity and mortality burden among patients with hypochondroplasia in England between 1998-2019

Presentation

  • Congresses
  • Hypochondroplasia
  • ACMG
  • 2024
  • Clinical Trial Data

Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results